Samples of human plasma having lipoprotein(a) (Lp[a]) protein levels between 5 and 15 mg/dl and a single apolipoprotein(a) (apo [a]) isoform were incubated in vitro at pH 7.7 with various concentrations (1-20 mM) of iV-acetylcysteine, homocysteine, 2-mercaptoethanol (2ME), and dithiothreitol (DTT) for 1 hour at 37°C under a nitrogen atmosphere. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblot analyses using a polyclonal antibody specific for apo(a) showed a progressive decrease In apo(a) immunoreactivity as a function of reductant concentration. This decrease of apo(a) immunoreactlvity was corroborated by enzyme-linked Immunosorbent assay (ELJSA) using anti-apo(a) as the capture antibody and either anti-apo B or anti-apo(a) as the developing antibody. In turn, there was no significant decrease in the immunoreactivity of apo B-100, as assessed by ELJSA using anti-apo B as both the capture and the detecting antibody. In the case of high concentrations of DTT the plasma samples had to be diluted to prevent gel formation on addition of the reductant. A progressive drop in immunoreactivity as a function of reagent concentration was also observed in pure preparations of Lp(a) incubated with the reducing agents at pH 7.7. At equivalent stoichiometries the changes were more marked than those observed with whole plasma, suggesting a quenching effect by the plasma proteins on the activity of the reductants. The changes in immunoreactivity were attended by dissociation of apo(a) from Lp(a) as assessed by Western blotting. This dissociation, which we interpret as the result of cleavage of the interchain disulfide bond(s), was complete at 5 mM DTT and 100 mM 2ME. In both cases the displaced apo(a) band exhibited a markedly reduced immunoreactivity. It is concluded that in vitro thiols and cysteine-containing compounds affect the immunoreactivity of apo(a), probably as a consequence of the cleavage of the intrakringle dlsulfides, and that at high reductant concentrations the immunologically altered apo(a) dissociates from Lp(a). These observations must be kept in mind when measuring Lp(a) in subjects with high plasma levels of cysteine-containing compounds and when examining apo(a) polymorphism by gel electrophoresis in the presence of the commonly used reagents such as DTT or 2ME. has shown that apo(a) has multiple kringle repeats, each characterized by three intrachain disulfide bridges in addition to an unpaired cysteine in kringle 4^ that is believed to be disulfide linked to another unpaired cysteine residue in the carboxyl terminal domain of apo B-100 (for review, see References 2 and 3). The sensitivity of these disulfides to the action of reducing agents has not been carefully examined except Received May 13, 1991; revision accepted December 10, 1991. for the demonstration that treating lipoprotein(a) (Lp[a]) with 1,4-dithiothreitol (DTT) or 2-mercaptoethanol (2ME) causes the dissociation of the interchain disulfide bond and the release of apo(a) from Lp(a). 2 -3 However, the effect of these and other reducing agents on the intrachain disulfides of the kringles of apo(a) and on the structure of Lp(a) has not been examined. Yet the information is important in understanding the structural-functional relation in Lp(a). To this end we have been examining the action on the kringle structure of apo(a) of agents with a potential destabilizing effect on disulfide bonds. In this article, we wish to report the results of a series of in vitro studies involving the incubation of either whole plasma or isolated Lp(a) with the cysteine-containing compounds N-acetylcysteine (NAC) and homocysteine (Hcys) and with the thiol reagents 2ME and DTT. We show that these agents have an important effect on apo(a) immunoreactivity that is likely to be secondary to the destabilization of the intrachain disulfides of the kringle domains.
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Angelo M. Scanu, Ditta Pfaffinger, Gunther M. Fless, Kazuhiko Makino, James Eisenbart, and Janet Hinman Samples of human plasma having lipoprotein(a) (Lp[a]) protein levels between 5 and 15 mg/dl and a single apolipoprotein(a) (apo[a]) isoform were incubated in vitro at pH 7.7 with various concentrations (1-20 mM) of iV-acetylcysteine, homocysteine, 2-mercaptoethanol (2ME), and dithiothreitol (DTT) for 1 hour at 37°C under a nitrogen atmosphere. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblot analyses using a polyclonal antibody specific for apo(a) showed a progressive decrease In apo(a) immunoreactivity as a function of reductant concentration. This decrease of apo(a) immunoreactlvity was corroborated by enzyme-linked Immunosorbent assay (ELJSA) using anti-apo(a) as the capture antibody and either anti-apo B or anti-apo(a) as the developing antibody. In turn, there was no significant decrease in the immunoreactivity of apo B-100, as assessed by ELJSA using anti-apo B as both the capture and the detecting antibody. In the case of high concentrations of DTT the plasma samples had to be diluted to prevent gel formation on addition of the reductant. A progressive drop in immunoreactivity as a function of reagent concentration was also observed in pure preparations of Lp(a) incubated with the reducing agents at pH 7.7. At equivalent stoichiometries the changes were more marked than those observed with whole plasma, suggesting a quenching effect by the plasma proteins on the activity of the reductants. The changes in immunoreactivity were attended by dissociation of apo(a) from Lp(a) as assessed by Western blotting. This dissociation, which we interpret as the result of cleavage of the interchain disulfide bond(s), was complete at 5 mM DTT and 100 mM 2ME. In both cases the displaced apo(a) band exhibited a markedly reduced immunoreactivity. It is concluded that in vitro thiols and cysteine-containing compounds affect the immunoreactivity of apo(a), probably as a consequence of the cleavage of the intrakringle dlsulfides, and that at high reductant concentrations the immunologically altered apo(a) dissociates from Lp(a). These observations must be kept in mind when measuring Lp(a) in subjects with high plasma levels of cysteine-containing compounds and when examining apo(a) polymorphism by gel electrophoresis in the presence of the commonly used reagents such as DTT or 2ME. has shown that apo(a) has multiple kringle repeats, each characterized by three intrachain disulfide bridges in addition to an unpaired cysteine in kringle 4^ that is believed to be disulfide linked to another unpaired cysteine residue in the carboxyl terminal domain of apo B-100 (for review, see References 2 and 3). The sensitivity of these disulfides to the action of reducing agents has not been carefully examined except for the demonstration that treating lipoprotein(a) (Lp[a]) with 1,4-dithiothreitol (DTT) or 2-mercaptoethanol (2ME) causes the dissociation of the interchain disulfide bond and the release of apo(a) from Lp(a). 2 -3 However, the effect of these and other reducing agents on the intrachain disulfides of the kringles of apo(a) and on the structure of Lp(a) has not been examined. Yet the information is important in understanding the structural-functional relation in Lp(a). To this end we have been examining the action on the kringle structure of apo(a) of agents with a potential destabilizing effect on disulfide bonds. In this article, we wish to report the results of a series of in vitro studies involving the incubation of either whole plasma or isolated Lp(a) with the cysteine-containing compounds N-acetylcysteine (NAC) and homocysteine (Hcys) and with the thiol reagents 2ME and DTT. We show that these agents have an important effect on apo(a) immunoreactivity that is likely to be secondary to the destabilization of the intrachain disulfides of the kringle domains.
Methods
The studies were carried out on 10 healthy male volunteers whose plasma Lp(a) protein levels were in the range 5-15 mg/dl with a single-band apo(a) isoform larger than that of apo B-100. After an overnight fast, 500 ml blood was collected into two 250-ml bottles containing, at a final concentration, 0.12% Na 2 EDTA, 0.01% NaN 3 , gentamicin sulfate (0.08 mg/ml blood), and kallikrein inhibitor (40 units/ml blood). Each donor signed the informed consent form approved by the Human Investigation Committee. The plasma was separated from the cells by centrifugation in a Beckman centrifuge (Beckman Instruments, Palo Alto, Calif.) at 3,000 rpm, 4°C, for 30 minutes and stored at this temperature no longer than 24 hours before use.
In a typical experiment, 1-ml aliquots of plasma were incubated for 1 hour at 37°C at pH 7.7 with 1, 2, 5, 10, and 20 mM concentrations of one of the following reagents: DTT, 2ME, NAC, and Hcys. Each tube was purged with nitrogen gas before capping. Aliquots of 10 fA of the incubated samples were separated on 2-16% polyacrylamide gradient gels (Pharmacia Fine Chemicals, Piscataway, N.J.) by electrophoresis (PAGE) in the presence of 0.2% sodium dodecyl sulfate (SDS), followed by immunoblotting using a specific polyclonal antibody against human Lp(a) that was raised in the rabbit, as previously described. 4 This antibody reacted with neither human plasminogen nor human apo B.
Studies were also carried out on Lp(a) preparations isolated from the plasma of the same blood donor using the procedure described by Fless et al. 4 In a typical experiment, purified Lp(a) was diluted to a concentration equivalent to the plasma level and mixed with concentrations ranging from 1 to 20 mM of DTT, 2ME, NAC, and Hcys followed by a 1-hour incubation at 37°C under nitrogen gas. Stock solutions (1 M) of each reducing agent were prepared before each experiment, adjusted to pH 7.7, kept under nitrogen, and used within 1 hour. At the end of the incubation, samples were immediately taken for analyses by enzyme-linked immunosorbent assay (ELISA) or Western blotting.
Experiments were also carried out to assess the mode of attachment of apo(a) to apo B-100 in Lp(a). Lp(a) at a concentration of 1 mg/ml was treated with either 6.2 M guanidine hydrochloride (GuHCl), 10 mM phosphate (pH 7.4), and 200 mM e-amino-n-caproic acid (EACA) in 10 mM phosphate (pH 7.4) or with 200 mM trans-Aaminomethylcyclohexanecarboxylic acid (tAMCHA) in 0.15 M NaCl, 10 mM phosphate, 0.01% Na 2 EDTA, and NaN 3 , pH 7.4, for 1 hour at room temperature. Identical incubations were also carried out in the presence of 10 mM DTT. Lp(a) incubated in 0.15 M NaCl, 10 mM phosphate, 0.01% Na 2 EDTA, and NaN 3 , pH 7.4, for 1 hour at room temperature served as a control. Lp(a) solutions (1 ml) in 6.2 M GuHCl were layered under a solution of 6 M GuHCl and 10 mM phosphate, pH 7.4. All other Lp(a) solutions were adjusted to d=1.25 g/ml with solid NaBr and layered under d=\2\ g/ml NaBr and 10 mM phosphate, pH 7.4, containing 200 mM EACA, 200 mM tAMCHA, or 0.15M NaCl. The solutions were centrifuged in an SW-55 rotor (Beckman) at 40,000 rpm at 20°C for 20 hours. In all cases either Lp(a) or Lp(a) devoid of apo(a) was concentrated in a layer 2-3 mm thick at the top of the centrifuge tube, removed by aspiration, and examined by SDS-gradient PAGE. In addition, 0.5-ml aliquots representing the bottom fraction were collected from each tube and examined for apo(a) on SDS-gradient PAGE.
Lp(a) quantification was carried out by the method of Fless et al 5 using anti-Lp(a) as the capture antibody and as the detecting antibody, either anti-apo B or antiapo(a). Quantification of apo B was carried out by using an ELISA in which goat anti-human apo B was used as both the capture and the detecting antibody. Total cholesterol was measured using a Kodak Ektachem DT-60 Analyzer (Kodak Instruments, Rochester, N.Y.). Total protein was measured by the Lowry method and the Bio-Rad protein assay in samples containing reductants (Bio-Rad kit, Richmond, Calif.).
Reagents
2ME was purchased from Bio-Rad Laboratories; DTT was from Calbiochem-Behring, La Jolla, Calif.; and Hcys as D,L-homocysteine and iodoacetic acid were purchased from Sigma Chemical Co., St. Louis, Mo. Crystalline NAC was obtained from Sigma or as a 20% solution from Quad Pharmaceuticals, Indianapolis, Ind.
Results

Studies With Whole Plasma
Effect of N-acetylcysteine and homocysteinc. Plasma samples incubated with either NAC or Hcys remained clear at all concentrations of the reagents as verified by measurements of turbidity at 600 nm. No changes in either total cholesterol or triglycerides were observed (data not shown). There was a progressive decrease in immunoreactivity of Lp(a) in the presence of increasing concentrations of these reducing agents as measured by ELISA, using either anti-apo B-100 or anti-apo(a) as the developing antibody ( Table 1 ). The drop in immunoreactivity was less severe when anti-apo(a) was used as the developing antibody in the ELISA. Contrary to the changes noted with the Lp(a) ELISA, there were no significant modifications in the antigenicity of plasma apo B as assessed by ELISA, using anti-apo B as both the capture and the detecting antibody.
By Western blotting analyses using polyclonal antiapo(a) as the detecting antibody (see representative SDS-gradient gels in Figure 1 ), the plasma samples incubated with either NAC or Hcys exhibited a decrease in the immunoreactrvity of the apo B-lOO-apo(a) band starting from the 10 mM concentration of each reagent; some dissociation of apo(a) from Lp(a) was seen at 20 mM concentration, but this was not a clear-cut band, probably because of attenuation in immunoreactivity. Overall, the results obtained by ELISA or Western blotting with NAC were comparable to those with Hcys. When a polyclonal antibody against apo B was used as the detecting antibody, no substantial changes in the intensity of the apo B band were observed, in agreement with the ELISA results (data not shown). The results obtained with ELISA and Western blotting were highly reproducible in the same individual regardless of the time of analysis and also among the plasma samples of the subjects studied.
Effect of dithiothreitol and 2-mercaptoethanol. As assessed by ELISA using either anti-apo B or anti-apo(a), the decrease in immunoreactivity caused by DTT was rather severe, whereas 2ME-treated samples behaved similar to those incubated with either NAC or Hcys (see Table 2 ). However, as we noted before, the drop was less severe when anti-apo(a) was used as the detecting antibody. Samples incubated with DTT had the lowest immunoreactrvity, which is in accord with the effectiveness of DTT as a reducing agent. In addition, plasma incubated with either 10 or 20 mM DTT formed an irreversible gel that was not observed when the other reducing agents were used at similar concentrations. The gel formation could be prevented by diluting the plasma two-to fivefold, depending on the plasma, before the addition of DTT. ELJSA of those samples showed a drop in immunoreactrvity of over 90% (data not shown). Western blotting of plasma samples reduced with DTT showed a marked drop in density of the apo B-apo(a) band and a dissociation of apo(a) from Lp(a) at higher concentrations of the reagent (Figure 1 ). In the case of 2ME, the effect on the immunoreactrvity was comparatively less. A complete dissociation between apo B-100 and apo(a) was only seen at high concentrations of the reagent, i.e., 100 mM, or 0.63% (vol/vol).
Studies With Pure Preparations of Lipoprotein(a)
Effect of reductants on immunoreactivity. ELISA of pure preparations of Lp(a), incubated with any of the reducing agents under consideration, exhibited a decrease in immunoreactivity that was significantly higher than that observed in the experiments with whole plasma, using either anti-apo B-100 or anti-apo(a) as the detecting antibodies. As noted before, loss of immunoreactivity was less severe when measured using anti-apo(a) as the detecting antibody (Table 3) . Western blotting using anti-apo(a) showed an attenuation in immunoreactivity that was particularly marked in the case of the DTT-treated samples (Figure 2 ), in agreement with the results obtained by ELISA. Complete dissociation of apo(a) from Lp(a) was observed at 5 mM DTT and 100 mM (0.63%, vol/vol) 2ME, accompanied by a marked decrease in immunoreactivity of the dissociated apo(a) band. Immunoblots of the same samples developed with anti-apo B showed an apo B-100 band in all samples that did not seem to vary in intensity with changing concentrations of thiol, in agreement with the results obtained with an ELISA for apo B. Experimental conditions were the same as those described in the footnote to Table 1 except that plasma treated with 10 and 20 mM DTT was not analyzed because of gel formation.
Apo, apolipoprotein; 2ME, 2-mercaptoethanol; DTT, dithiothreitol.
Effect of nonreducing agents on apolipoprotein B-100-apolipoprotein(a) linkage.
Despite the general belief that apo(a) is linked to apo B-100 of the Lp(a) via disulfide bond(s), the possibility exists that apo(a) is attached to apo B by noncovalent interactions between the kringle domains of apo(a) and lysine-rich regions of apo B-100. To assess the latter assumption we treated Lp(a) with various agents designed to disrupt these interactions in the presence or absence of 10 mM DTT (see Table 4 ). The results indicated that 6 M GuHCl, which is regarded as a solvent that eliminates all noncovalent interactions in proteins, was unable to dissociate apo(a) from Lp(a). This was also true for the lysine analogues EACA and tAMCHA, which theoretically compete with the lysinerich regions of apo B-100 for the kringle domains of apo(a) and thereby cause dissociation of apo(a) from Lp(a). Apo(a) was dissociated from Lp(a) only in the presence of 10 mM DTT, thus supporting the concept of a disulfide linkage between apo(a) and apo B-100.
Discussion
The results of the present studies have shown that in vitro, the cysteine-containing compounds NAC and Hcys and the thiol-containing reagents 2ME and DTT can cause different degrees of structural changes of apo(a) that lead to an attenuation of its immunoreactivity. The structural changes were reproducible in the same individual and among the individuals studied. Although this report deals only with subjects with a single apo(a) band phenotype, we observed similar results in double-band phenotypes (A.M. Scanu, un- Purified lipoprotein(a) was diluted with saline to a concentration equivalent to that of the plasma sample from which the lipoprotein was derived. Other experimental conditions were the same as in the footnote to Table 1 .
Apo, apolipoprotein; NAC, N-acetylcysteine; Hcys, homocysteine; 2ME, 2-mercaptoethanol; DTT, dithiothreitol. published results). The observed structural changes were likely to be secondary to the cleavage of the intrachain disulfide bonds of the apo(a) kringles that appeared while this glycoprotein was still linked to apo B-100, as deduced from the results of Western blot analyses. More marked changes occurred once apo(a) was dissociated from apo B-100 at high concentrations of the reductants. The ELISA for Lp(a) in these experiments used anti-apo(a) as the capture antibody and alkaline phosphatase-conjugated anti-apo B or antiapo(a) as the detecting antibody. The loss of immunoreactivity that was detected by anti-apo B could not be accounted for by apo B-100, as this protein exhibited no significant changes in immunoreactivity, but could be accounted for by the cleavage of the disulfide bond linking the apo B-lOO-apo(a) complex because on incubation of Lp(a) with the capture antibody-coated ELJSA well, only apo(a) would have remained on the plate. The lack of changes in the immunoreactivity of apo B-100 incubated with the reducing agents is in accord with the observations of Gries et al, 6 who reported that apo B-100 did not undergo detectable conformational changes on reduction. Thus, we may conclude that the decrease in immunoreactivity that was detected by anti-apo(a) was likely the consequence of the action of the reducing a] ) was treated with various reagents and then subjected to centrifugal conditions designed to separate the Lp(a) particle from dissociated apolipoprotein(a) (apo[a] ). Plus sign indicates that apo(a) was recovered at either the top or the bottom of the centrifuge tubes. When dissociation occurred, apo(a) was recovered in the bottom of the tube. Undissociated apo(a) floated at the top.
Cone, concentration; DTT, dithiothreitol; GuHQ, guanidine hydrochloride; tAMCHA, fra/u-4-aminomethylcyclohexanecarboxylic acid.
agents on the kringles of apo(a), which started occurring before the dissociation of apo(a) from the apo B-100-apo(a) complex. The isolated preparations of Lp(a) that were incubated with the reductants also exhibited a decrease in immunoreactivity, although it was significantly higher than that observed with whole plasma at equivalent stoichiometries because either Lp(a) is structurally more stable in the plasma milieu and/or the plasma caused some quenching of the activity of the reductants. The formation of a gel in plasma samples incubated with high concentrations of DTT would favor the latter interpretation.
Overall, these results point to the critical role played by the disulfide bonds in kringle structure and to the potential problems attending the measurement of plasma Lp(a) levels in the presence of either thiols or cysteine-containing compounds because of the possibility of generating false low values. A case in point may be the results recently reported by Gavish and Breslow, 7 who observed a decrease of the plasma levels of Lp(a) in two patients after a short-term oral intake of NAC at a dosage of 2 or 4 g/day. Their suggestion that NAC acted at the liver level and either prevented the formation or caused the cleavage of the disulfide linkage between apo(a) and apo B-100 must be viewed as too speculative because the tissue NAC concentration was not known. We must also keep in mind that NAC, while causing dissociation of apo(a) from Lp(a), may also cause structural changes of apo(a). Because of its denaturing potential NAC may be viewed as an unfavorable agent from a cardiovascular standpoint because of a potential for toxicity. We should also point out that Stalenhoef et al 8 failed to observe a significant effect on the plasma levels of Lp(a) after oral intake of NAC. In view of these discrepancies it appears advisable that plasma levels of NAC be monitored when this reductant is used for therapeutic purposes. Relevant to this discussion are the recent data by Trieu et al, 9 indicating that DTT in 10 mM concentrations prevents the bonding of recombinant apo(a) to low density lipoprotein 2 , and thus suggesting that apo(a) may be linked to apo B-100 by interactions in addition to the disulfide bond. In this study we examined the issue again by subjecting Lp(a) to the action of chemical agents expected to dissociate noncovalent interactions between these two proteins ( Table 4) . The results supported the prevalent opinion that the link between apo B-100 and apo(a) in Lp(a) occurs via disulfide bond(s).
A general comment is in order. The techniques for measuring plasma Lp(a) level have not yet been standardized, in part because of the variety of antibodies used, i.e., polyclonals and monoclonals, and in part because of the varying experimental conditions from laboratory to laboratory (for review, see Reference 3). In consequence, a wide range of results has been reported even in the normal population. It is now apparent that difficulties may also arise when examining the plasma of subjects who are taking drugs that might have an effect on the structure of the kringles that are so abundant in apo(a). These effects may not be limited to Lp(a) but may occur in other proteins containing kringle structures, such as plasminogen, 10 particularly in clinical situations that are associated with an increased plasma level of cysteine-containing compounds. It should also be apparent that when used in assessing apo(a) poly-morphism by gel electrophoresis techniques, thiols or cysteine-containing reagents may confound the interpretation of the results, particularly in subjects with low plasma Lp(a) levels in which low-abundance isoforms may pass undetected.
